SEC Form 4 · accession 0001179110-17-001394
OSIRIS THERAPEUTICS, INC. · OSIR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rodrigo Alberto Avendano
Officer — Chief Medical Officer
Period of report
Jan 27, 2017
Accepted (ET)
Jan 31, 2017 · 5:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001360886
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Options (right to buy)F1 | $4.96 | Jan 27, 2017 | D | 5,000 | D | Oct 3, 2017 | Oct 3, 2026 | Common Stock | 5,000 | 15,000 | D |
| Incentive Stock Option (right to buy)F1 | $4.96 | Jan 27, 2017 | D | 5,000 | D | Oct 3, 2018 | Oct 3, 2026 | Common Stock | 5,000 | 10,000 | D |
| Incentive Stock Option (right to buy)F1 | $4.96 | Jan 27, 2017 | D | 5,000 | D | Oct 3, 2019 | Oct 3, 2026 | Common Stock | 5,000 | 5,000 | D |
| Incentive Stock Option (right to buy)F1 | $4.96 | Jan 27, 2017 | D | 5,000 | D | Oct 3, 2020 | Oct 3, 2026 | Common Stock | 5,000 | 0 | D |
Explanation of responses
- F1Unvested incentive stock option that were forfeited concurrent with the Reporting Person's separation from the company, consistent with the provisions of the Amended and Restated 2006 Omnibus Plan.